The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - AstraZeneca; Foundation Medicine; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech; Takeda
Research Funding - AstraZeneca; Hengrui Pharmaceutical; Pfizer; Pfizer; Revolution Medicines; Roche/Genentech; Spectrum Pharmaceuticals; Takeda; TP Therapeutics
Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
 
Edward S. Kim
Honoraria - AstraZeneca; Celgene; Lilly
Consulting or Advisory Role - AstraZeneca; Celgene; Lilly
 
Sai-Hong Ignatius Ou
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Ignyta (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Hutchison MediPharma; Sanomics Limited
Stock and Other Ownership Interests - Hutchison MediPharma; Sanomics Limited
Honoraria - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Fishawack Facilitate; Hutchison MediPharma; Ignyta; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Vertex
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Hutchison MediPharma; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst)
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Veronica Bunn
Employment - Millennium
 
Pingkuan Zhang
Employment - Millennium